Literature DB >> 15013685

The androgen receptor: a potential target for therapy of prostate cancer.

A F Santos1, H Huang, D J Tindall.   

Abstract

The androgen receptor plays a pivotal role in the prostate. Its primary function is to provide responsive gene products for differentiation and growth, but under abnormal conditions it contributes to the development of prostate cancer. The goal of this review is to elucidate the molecular functions of the androgen receptor and its role in prostate cancer. Initially the function of the androgen receptor will be described. Next, the clinical diagnosis, epidemiological impact, and treatments of androgen-dependent and -independent prostate cancer will be discussed. Finally we will examine how the mechanism of androgen action has played a role in the translation of new therapies and how this may influence future treatment modalities of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013685     DOI: 10.1016/j.steroids.2003.10.005

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  18 in total

Review 1.  Progress of molecular targeted therapies for prostate cancers.

Authors:  Weihua Fu; Elena Madan; Marla Yee; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2011-11-29

2.  First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

Authors:  Puranik Purushottamachar; Aakanksha Khandelwal; Pankaj Chopra; Neha Maheshwari; Lalji K Gediya; Tadas S Vasaitis; Robert D Bruno; Omoshile O Clement; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

3.  An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.

Authors:  Xu-Bao Shi; Lingru Xue; Joy Yang; Ai-Hong Ma; Jianjun Zhao; Ma Xu; Clifford G Tepper; Christopher P Evans; Hsing-Jien Kung; Ralph W deVere White
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-03       Impact factor: 11.205

4.  Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum.

Authors:  Ya-Ping Liu; Guo-Fu Hu; Yun-Xia Wu
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

5.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

Authors:  Shen Gao; Peng Lee; Hua Wang; William Gerald; Michael Adler; Liying Zhang; Yun-Fang Wang; Zhengxin Wang
Journal:  Mol Endocrinol       Date:  2005-02-24

6.  Altered differentiation and proliferation of prostate epithelium in mice lacking the androgen receptor cofactor p44/WDR77.

Authors:  Shen Gao; Hong Wu; Fen Wang; Zhengxin Wang
Journal:  Endocrinology       Date:  2010-06-02       Impact factor: 4.736

7.  Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Authors:  Jian Yang; Shuo Wei; Da-Sheng Wang; Yu-Chieh Wang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2008-03-13       Impact factor: 7.446

Review 8.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

9.  Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.

Authors:  Kristin A Raclaw; Hannelore V Heemers; Emily M Kidd; Scott M Dehm; Donald J Tindall
Journal:  Prostate       Date:  2008-11-01       Impact factor: 4.104

10.  PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient: A Case Report.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel
Journal:  Case Rep Oncol       Date:  2009-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.